Abstract 619P
Background
In recent years, the environmental health issue of microplastics has aroused increasingly greater source of concern. Some studies suggested that exposure to polystyrene microplastics (PS-MPs) may lead to renal inflammation and oxidative stress in animals. However, there is little known about the essential effects of PS-MPs with high-fat diet (HFD) on the renal development and microenvironment.
Methods
In this study, we provided the single-cell transcriptomic landscape of the kidney injury and immune cells population induced by PS-MPs and HFD in mouse model by unbiased single-cell RNA sequencing (scRNA-seq).
Results
showed that PS-MPs could accumulate in kidney, and PS-MPs exposure with HFD treatment largely reshape cellular components in mouse kidneys. First, we found that PS-MPs act on renal epithelial cells, specifically the proximal and distal convoluted tubule cells, to exacerbate the kidney burden induced by HFD, and promote MAPK and PARP signaling pathways. Second, PS-MPs exposure and and HFD treatment indicated activated oxidative phosphorylation and reactive oxygen species (ROS) mediated chemical carcinogenesis of mural cells. Besides, PS-MPs exposure markedly increased activation and proliferation of effective T cells, and down-regulated B cells activation. Meanwhile, PS-MPs exposure prominently increased the level of macrophages infiltration in mononuclear phagocytes, especially up-regulated the pro-inflammatory CXCL2+ macrophages and M2-like PF4+ macrophages subpopulation, which participated in the lysosome and ROS-mediated chemical carcinogenesis. Multispectral immunofluorescence and immunohistochemistry identified PF4+ macrophages in samples with human tumor-adjacent kidney and renal cell carcinoma. The activation of PF4+ macrophages mainly interacted with fibroblasts and injured renal tubular cells, and promoted the fibrosis process after renal injury.
Conclusions
In conclusion, this study systematically revealed molecular variation of both renal cells and immune cells in mice kidney microenvironment induced by PS-MPs and HFD, which provided a molecular basis for understanding the genitourinary injury mechanism of PS-MPs in mammals.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
183P - Final analysis of phase II clinical study evaluating the safety and effectiveness of neoadjuvant S-1 + oxaliplatin combination therapy for older patients with locally advanced gastric cancer
Presenter: Eiji Oki
Session: Poster Display
Resources:
Abstract
184P - Neutropenia as a predictive and prognostic factor in nanoliposomal-irinotecan/fluorouracil/leucovorin therapy for pancreatic cancer: Findings from the NAPOLEON-2 study (NN-2301)
Presenter: Yuki Sonoda
Session: Poster Display
Resources:
Abstract
185P - Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
186P - Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial
Presenter: Xiaoting Ma
Session: Poster Display
Resources:
Abstract
187P - Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)
Presenter: Yongguang Wei
Session: Poster Display
Resources:
Abstract
188P - Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Margherita Rimini
Session: Poster Display
Resources:
Abstract
189P - Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Shun Yamamoto
Session: Poster Display
Resources:
Abstract
190P - Perioperative camrelizumab combined with chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, single-center, phase II clinical trial
Presenter: Jiaxing He
Session: Poster Display
Resources:
Abstract
191P - Predictive value of CXCR6 expression in gastric cancer survival and immune modulation
Presenter: Song-Hee han
Session: Poster Display
Resources:
Abstract
192P - Antiangiogenesis-related adverse events (ARAE) to predict efficacy in patients with advanced gastric cancer (AGC) treated with apatinib + chemotherapy: Results from two prospective studies
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract